GlassScriptPhysician profile
Kayla Murphy Smith
NPI 1215422480
$5,030.65
in general payments reported to CMS, 2019-2025
22 companies · $1,298 in 2025
The $1,298 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $784 · 2022: $585 · 2023: $1,139 · 2024: $1,225 · 2025: $1,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,582 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,582.23 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,000.75 | 2021-2025 | Farxiga, Wainua, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $978.61 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $738.32 | 2021-2025 | Verquvo, Capvaxive |
| Alnylam Pharmaceuticals INC. | $357.15 | 2022-2025 | Amvuttra, Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $279.80 | 2024-2025 | |
| Pfizer INC. | $243.30 | 2022-2025 | |
| Impulse Dynamics (USA) INC. | $215.67 | 2022-2023 | Optimizer |
| Scpharmaceuticals INC. | $205.94 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $143.07 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $142.02 | 2021-2024 | Lifevest |
| Abbvie INC. | $141.02 | 2021-2022 | |
| Ucb, INC. | $128.81 | 2025 | Rystiggo |
| Lexicon Pharmaceuticals, INC. | $124.15 | 2023-2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $92.15 | 2022-2023 | Uptravi, Opsumit |
| Vanda Pharmaceuticals INC. | $67.09 | 2024 | Fanapt, Hetlioz |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $43.73 | 2021 | |
| Bridgebio Pharma, INC. | $35.92 | 2025 | Attruby |
| Medtronic, INC. | $26.13 | 2024 | Biobutton |
| Boston Scientific Corporation | $23.12 | 2023 | Watchman |
| Novo Nordisk INC | $17.05 | 2023 | Rybelsus |
| Vifor Pharma, INC. | $14.07 | 2021 | |
| Daiichi Sankyo INC. | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.